Inhibikase Therapeutics (IKT) Debt to Equity (2020 - 2025)
Historic Debt to Equity for Inhibikase Therapeutics (IKT) over the last 6 years, with Q2 2025 value amounting to $0.0.
- Inhibikase Therapeutics' Debt to Equity fell 9841.3% to $0.0 in Q2 2025 from the same period last year, while for Jun 2025 it was $0.0, marking a year-over-year decrease of 9841.3%. This contributed to the annual value of $0.0 for FY2024, which is 9147.94% down from last year.
- Per Inhibikase Therapeutics' latest filing, its Debt to Equity stood at $0.0 for Q2 2025, which was down 9841.3% from $0.0 recorded in Q1 2025.
- Inhibikase Therapeutics' Debt to Equity's 5-year high stood at $0.03 during Q1 2021, with a 5-year trough of -$0.27 in Q3 2024.
- Moreover, its 5-year median value for Debt to Equity was $0.01 (2023), whereas its average is -$0.01.
- The largest annual percentage gain for Inhibikase Therapeutics' Debt to Equity in the last 5 years was 29289.55% (2024), contrasted with its biggest fall of 285785.65% (2024).
- Over the past 5 years, Inhibikase Therapeutics' Debt to Equity (Quarter) stood at $0.01 in 2021, then soared by 31.06% to $0.01 in 2022, then surged by 97.21% to $0.01 in 2023, then tumbled by 91.48% to $0.0 in 2024, then tumbled by 59.31% to $0.0 in 2025.
- Its last three reported values are $0.0 in Q2 2025, $0.0 for Q1 2025, and $0.0 during Q4 2024.